Pontifax Venture Capital — 2023 Investments
2 investments dated 2023 · listed companies and verified rows first · show all
Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.
BiotechHealthtechNewton, US
Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)
Board seatTomer Kariv· per SEC Form D
Co-investorsBain Capital Life SciencesNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalSanofi VenturesMass General Brigham Ventures+8 more
UroGen is a biopharmaceutical company developing and commercializing treatments for urological cancers, including FDA-approved therapies such as JELMYTO and ZUSDURI built on its RTGel technology.
BiotechHealthtechPrinceton, US
Elizabeth Barrett(Executive Officer, Director)Mark Schoenberg, M.D.(Executive Officer)Jason Smith(Executive Officer)Arie Belldegrun, M.D.(Director)Dan Wildman(Director)Don Kim(Executive Officer)
Board seatRan Nussbaum· per SEC Form D
Co-investorsAisling CapitalMonograph Capital Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.